Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma

Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma

Abstract Background Immunotherapy plays a key role in the treatment of metastatic melanoma. Patients with autoimmune conditions and/or on immunosuppressive therapy due to orthotropic transplants, however, are systematically excluded from clinical trials. Talimogene laherparepvec (T-VEC) is the first...

Full description

Bibliographic Details
Main Authors: Gustavo Schvartsman, Kristen Perez, Jill E. Flynn, Jeffrey N. Myers, Hussein Tawbi
Format: Article
Language:English
Published: BMJ Publishing Group 2017-06-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Cancer
Melanoma
Immunotherapy
Allotransplant
Rejection
T-VEC
Online Access:http://link.springer.com/article/10.1186/s40425-017-0250-5

Internet

http://link.springer.com/article/10.1186/s40425-017-0250-5

Similar Items